Uromigos-ASCO
Advertisement
Dr. Gerhardt Attard discusses practice-changing data from AMPLITUDE, and the history of PARP inhibitor use.
Dr. Nick James discusses data from STAMPEDE on the use of AI to predict benefit from ADT + abiraterone.
Dr. Jorge Garcia discusses the process of selecting abstracts for oral presentation.
Dr. Toni Choueiri discusses this combination cohort of HIF inhibition plus VEGF-R inhibition.
Dr. Matt Galsky discusses the 2025 ASCO Annual Meeting data regarding ctDNA from the NIAGARA study.
Dr. Jeannie Hoffman-Censits discusses her randomized phase 2 trial on adding sacituzumab govitecan to maintenance avelumab.
Dr. Michiel Van Der Heijden joins the podcast to discuss his trial on ipilimumab + nivolumab vs chemotherapy randomization.
Dr. Monty Pal discusses more correlative data from the IMmotion010 trial, including matched baseline samples.
Dr. McDermott recaps his discussion on biomarkers in kidney cancer from the 2025 ASCO Annual Meeting.
Silke Gillessen joins Tom and Brian, who give their opinion on new data presented at the conference.
David McDermott discusses the adjuvant vs neoadjuvant trial and its wider implications for the genitourinary oncology field.
Dr. Guru Sonpavde describes the efficacy of chemotherapy with nivolumab in lymph node-only first-line UC patients.
Dr. Laurence Albiges discusses this biomarker which may have predictive and prognostic capabilities for kidney cancer.
Toni Choueiri and Brian describe similarities and differences in the biomarker findings of the KN426 and CLEAR trials.
Dr. Andrea Necchi describes the efficacy and toxicity of neoadjuvant sacituzumab govitecan in urothelial carcinoma.
Dr. Jonathan Rosenberg breaks down the data available for the bladder cohort from the DESTINY-PanTumor02 trial.
Dr. Alex Wyatt describes the predictive capabilities of ctDNA in determining outcomes in the TheraP trial.
Dr. Christos Kyriakopoulos describes the outcome of the CHAARTED-2 study for castration-resistant prostate cancer.
Silke Gillessen joins Brian and Tom to give a preview of this year's ASCO annual meeting.
Yohann Loriot, MD, PhD, discusses the practice-changing THOR study data on the benefit of erdafitinib for advanced UC.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.